Paul Koker

Statistics

Publications

Citations

368

H-Index

Active since

1995

Affiliations

Boehringer Ingelheim (United States)(Current)

Boehringer Ingelheim (Germany)

Boehringer Ingelheim (Canada)

Paul Koker is an author at Boehringer Ingelheim (United States) specializing in pharmacotherapy, chronic obstructive pulmonary disease, and pulmonology.

Publications per year

1995–2015

Publications

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis

Michael W. Konstan, Gerd Döring, Sonya L. Heltshe et al. · Journal of Cystic Fibrosis · 2014 · 135 citations · Full text

Medicine, Pediatrics, Pharmacotherapy +13

Effect of Ipratropium Bromide Treatment on Oxygen Saturation and Sleep Quality in COPD

Richard J. Martin, Becki L. Bucher Bartelson, Philip L. Smith et al. · CHEST Journal · 1999 · 116 citations

Medicine, Internal Medicine, Pharmacotherapy +14

A dose-response study of the efficacy and safety of ipratropium bromide nasal spray in the treatment of the common cold

Louis S. Diamond, Robert J. Dockhorn, Jay Grossman et al. · Journal of Allergy and Clinical Immunology · 1995 · 55 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results

Judy Bradley, Paul Koker, Qiqi Deng et al. · PLoS ONE · 2014 · 29 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

Four Weeks Once Daily Treatment with BI 1744 CL, a Novel Long-Acting ß <sub>2</sub> -Agonist, Is Effective in COPD Patients.

JA van Noord, Lawrence Korducki, AL Hamilton et al. · 2009 · 17 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +11

1–5 of 6